| Curtiss D Farrell, MD | |
|
510 S Park Dr, Broken Bow, OK 74728-5330 | |
| (580) 584-3449 | |
| (580) 584-3451 |
| Full Name | Curtiss D Farrell |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 510 S Park Dr, Broken Bow, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588639827 | NPI | - | NPPES |
| 2570 | Other | NE | MIDLANDS CHOICE |
| 31047 | Other | NE | BCBS |
| Entity Name | Greater Phoenix Collaborative Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750686614 PECOS PAC ID: 0941503304 Enrollment ID: O20160120000300 |
News Archive
The U.S. Chamber of Commerce Business Civic Leadership Center (BCLC) is recognizing Health Care Service Corporation (HCSC) for its outstanding work with community service. The BCLC has named HCSC as a finalist for its Corporate Citizenship Award in the category of U.S. Community Service. The U.S. Chamber of Commerce is the world's largest business federation and HCSC is the country's largest customer-owned health insurer operating Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas.
Predicting the beginning of influenza outbreaks is notoriously difficult, and can affect prevention and control efforts.
Qualified urologists and urology departments collaborating with microbiologists and infectious disease specialists are encouraged to join the new Global Prevalence Study of Infections in Urology (GPIU) with the last five calendared dates taking place this week and by the end of this month.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) first quarter ended July 31, 2010.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Curtiss D Farrell, MD 1301 E Lincoln Rd, Idabel, OK 74745-7300 Ph: (580) 208-3100 | Curtiss D Farrell, MD 510 S Park Dr, Broken Bow, OK 74728-5330 Ph: (580) 584-3449 |
News Archive
The U.S. Chamber of Commerce Business Civic Leadership Center (BCLC) is recognizing Health Care Service Corporation (HCSC) for its outstanding work with community service. The BCLC has named HCSC as a finalist for its Corporate Citizenship Award in the category of U.S. Community Service. The U.S. Chamber of Commerce is the world's largest business federation and HCSC is the country's largest customer-owned health insurer operating Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas.
Predicting the beginning of influenza outbreaks is notoriously difficult, and can affect prevention and control efforts.
Qualified urologists and urology departments collaborating with microbiologists and infectious disease specialists are encouraged to join the new Global Prevalence Study of Infections in Urology (GPIU) with the last five calendared dates taking place this week and by the end of this month.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) first quarter ended July 31, 2010.
› Verified 5 days ago